Targeted immunotherapy is revolutionizing cancer therapy by harnessing the specificity of targeted therapy and the strength of the immune system. The session "Targeted Immunotherapy" addresses approaches that maximize immune responses to cancer while respecting effects on normal tissues.".
This strategy includes recognizing particular tumor antigens or molecular targets and targeting immune cells or therapeutic agents to them. Methods include monoclonal antibodies, bispecific T-cell engagers, CAR T-cell therapy, and checkpoint inhibitors designed to target tumor-specific pathways. Through the highly specific activation of the immune system, targeted immunotherapy can enhance the efficacy of treatment and minimize systemic toxicity.
The session also discusses combination approaches, wherein the targeted immunotherapies are combined with chemotherapy, radiation, or other immunomodulatory therapies to better overcome resistance and improve responses. Biomarkers and genomic profiling are essential for identifying patients most likely to benefit from such therapies and for measuring treatment response.
Delegates will learn about the mechanisms, clinical utility, and novel developments in targeted immunotherapy. This session highlights the way precision-guided immune approaches are redefining the oncology field, providing better, more personalized, and safer treatment for patients around the globe.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
